F2G’s hopes of getting the first in a brand-new class of antifungals to market have hit a setback courtesy of a complete response letter from the FDA. The regulator was due to make a call on approving ...
A research team at McMaster University has discovered a new drug class that could someday lead to breakthrough treatments for dangerous fungal infections. The new molecules, dubbed coniotins, were ...
Pharmaceutical firms are making progress in addressing the need for new antifungal therapies. F2G says olorofim is part of the first new class of antifungals to be developed in 20 years. F2G’s chief ...
After living with a severe fungal allergy for about 40 years, Jill Fairweather is running out of treatment options. Now 65, Fairweather was diagnosed with aspergillosis, a disease caused by the common ...
Researchers on Wednesday reported two promising new approaches to counteract malaria’s growing resistance to medication — one ...
In a Class I recall, the most serious type, a New Jersey drugmaker is removing 17,376 drug cartons from the market because of a cross-contamination risk. Scynexis is recalling two lots of Brexafemme ...
RESEARCH TRIANGLE PARK – Durham-based Mycovia Pharmaceuticals has received its first product approval from the U.S. Food and Drug Administration. The FDA granted marketing clearance for VIVJOA ...
A research team at McMaster University has discovered a new drug class that could someday lead to breakthrough treatments for dangerous fungal infections. The new molecules, dubbed coniotins, were ...
Researchers at the Optics and Photonics Research Center (CePOF) have succeeded in increasing the susceptibility of the fungus Candida albicans to drug treatment through light-activated therapy. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback